Interaction Checker

Apps

Download from the AppStore

Download from Google Play

Interaction Checker
About Us
Mission Statement Meet the Team Steering Committee
Interaction Checkers
Interaction Checker Español Checker Português Checker Interaction Checker Lite View All Checker
Prescribing Resources Videos Site News
Contact Us
Feedback Form Suggest a Drug
Support Us
Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Potential Interaction

Darunavir/cobicistat (DRV/c)

Amlodipine

Quality of Evidence: Very Low

Summary:

Coadministration has not been studied. Amlodipine is metabolized by CYP3A4. Darunavir/cobicistat could potentially increase amlodipine exposure. Caution is warranted and clinical monitoring of therapeutic and adverse effects is recommended. Amlodipine should be started at low doses with careful titration to response.

Description:

Based on theoretical considerations darunavir/cobicistat is expected to increase amlodipine plasma concentrations (CYP3A and/or CYP2D6 inhibition). Clinical monitoring of therapeutic and adverse effects is recommended when these medicines are co-administered with darunavir/cobicistat.
Rezolsta Summary of Product Characteristics, Janssen-Cilag Ltd, July 2023.

Coadministration is expected to increase concentrations of amlodipine. Clinical monitoring is recommended for co-administration with calcium channel blockers metabolized by CYP3A.
Prezcobix US Prescribing Information, Janssen Pharmaceuticals Inc, March 2023.

View all available interactions with Darunavir/cobicistat (DRV/c) by clicking here.

SPONSORS
EDITORIAL SPONSORS
Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017
healthline-best-HIV-and-AIDS-apps-of-2019
building_better_healthcare_awards_2016 healthline-best-HIV-and-AIDS-apps-of-2016
Cookie Policy Privacy Statement Terms & Conditions

Copyright © 2024 The University of Liverpool. All rights reserved.